Blood thinner apixaban tested for late clots after spleen surgery
NCT ID NCT07461532
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the blood thinner apixaban can dissolve blood clots in the portal vein that develop more than a year after laparoscopic spleen surgery in people with cirrhosis. Twenty participants will take apixaban twice daily, and doctors will use ultrasound or CT scans to see if the clots shrink or disappear. If successful, patients will continue apixaban long-term to prevent recurrence.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
apixaban
What this could lead to
If effective, apixaban could offer a safe way to dissolve late-occurring portal vein clots after spleen surgery, potentially preventing serious complications.
What could go wrong
This is a very small early study with only 20 participants, so results may not apply broadly. Patients must take apixaban indefinitely if it works, and bleeding risks are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Medical College
RECRUITINGYangzhou, Jiangsu, 225001, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••